News

Kyrexa lands angel backing for £1.5M push on oral dog cancer drug

What's the deal? Animal Health AngelsDealroom has a profile for this one. Try Dealroom → has invested in KyrexaDealroom has a profile for this one. Try Dealroom →, a UK startup developing Rimcazole, an oral immunotherapy for canine cancer. The angel group's members backed the company as it raises £1.5 million to fund further clinical development.

What's the endgame? Kyrexa, co-founded by specialist vet Clare Knottenbelt and physician scientist Barbara Spruce, is building what it calls the world's first oral immunotherapy for canine cancer. Rimcazole combines anti-tumour, anti-angiogenic, and immune effects in a single small molecule, offering an alternative to costly biologics.

Why now? Early pilot data from 30 dogs with advanced cancers showed tumour responses alongside a high quality of life, according to Kyrexa. The company has secured MUMS designations in two cancer indications and is targeting US Food and Drug Administration conditional approval by 2030.

What's the backdrop? Kyrexa says many diagnosed dogs still receive no advanced treatment, left unserved by existing drugs or priced out by specialist care. "Veterinary oncology is a fast-growing area, yet many dogs diagnosed with cancer still receive no advanced treatment," said Wendy Furness, director at Animal Health Angels.

What could go wrong? The raise is modest and early-stage, and available reports do not confirm the round is complete. An interview in July said about £500,000 had been secured at that point, leaving much of the target to close.

The signal: Investor appetite for veterinary oncology is building. In October, US startup Familiar Therapeutics launched with a $5 million seed round for canine and feline medicines, including an oncology candidate — a sign that pet cancer is drawing fresh early-stage capital.

Read more: ukbaa.org.uk

Image credit: S.C. Air National Guard

More top stories